Related Experiment Video
Updated: Jul 11, 2026
08:47
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
Therapeutic studies in hepatic encephalopathy.
Kevin D Mullen1, Piero Amodio, Marsha Y Morgan
1Department of Gastroenterology/Hepatology, MetroHealth Medical Center, Cleveland, OH, USA.
Metabolic Brain Disease
|September 22, 2007
Summary
This review discusses therapeutic studies for hepatic encephalopathy. It covers the rationale for placebo-controlled trials and details outcome measures for clinical and research settings.
Area of Science:
- Hepatology
- Clinical Trials
Background:
- Presentations from the 4th International Hannover Conference on Hepatic Encephalopathy (2006) form the basis of this article.
- Focuses on therapeutic strategies and study design within hepatic encephalopathy research.
Purpose of the Study:
- To review the justification for employing placebo-controlled trials in hepatic encephalopathy research.
- To detail outcome parameters essential for evaluating therapeutic interventions in both clinical and research environments.
Main Methods:
- Compilation of expert presentations on therapeutic studies in hepatic encephalopathy.
- Discussion of methodological considerations for clinical trials.
Main Results:
- The article emphasizes the importance of placebo-controlled trials for robust therapeutic evaluation.
- Detailed discussion on defining and measuring outcomes in hepatic encephalopathy studies.
Conclusions:
- Standardized outcome parameters are crucial for advancing therapeutic research in hepatic encephalopathy.
- Placebo-controlled trials provide a necessary benchmark for assessing treatment efficacy.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...